Mentioned in ?
References in periodicals archive ?
Insmed Incorporated (Nasdaq: INSM) announced that it has completed the New Drug Application (NDA) to seek regulatory approval of SomatoKine(R) (Mecasermin rinfabate) for the treatment of growth hormone insensitivity syndrome.
SomatoKine(R) is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).
Insmed's most advanced product, SomatoKine(R), is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).
rhIGF-I/rhIGFBP-3 is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).
Insmed's most advanced product, rhIGF-I/rhIGFBP-3, is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).

Full browser ?